GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Evening networking is a punishment for working parents – Mark Debono
The issue, he argues, lies in how professional life continues to be structured as if parenting does not exist.
ITS appoints Simon Caurana as Director of Centre of Contemporary Tourism
This role requires him to serve as the founding strategic leader of the newly established centre.
Thomas Agius Ferrante appointed CEO of Xara Collection
Thomas Agius Ferrante will focused on strengthening The Xara Collection as one of Malta’s most known hospitality companies.
Andrew Hogg is The Brewhouse Malta’s new Business Development Manager
Andrew Hogg is also Executive Director at The BrewHouse Malta.
